Maarten Cozijnsen

128 Table 3. Overview of studies that compared the safety of combination therapy with anti-TNF monotherapy in pediatric and adult IBD patients Type Year Authors Patients N Treatment Duration Post-hoc analysis of RCT* 2014 Rosh et al(44) Pediatric CD 192 [1] ADA+IM [2] ADA 1-5 years Observational 2013 Colletti et al (DEVELOP)(45) Pediatric CD&UC 4343 [1] Anti-TNF+IM [2] Anti-TNF` [3] IM RCT 2014 Colombel et al (SONIC)(11) Adult CD 508 [1] IFX+AZA; [2] IFX+PCB; [3] AZA+PCB 26 wks RCT 2014 Panaccione et al (UC SUCCESS)(12) Adult UC 239 [1] IFX+AZA; [2] IFX+PCB; [3] AZA+PCB 8 wks RCT 2010 Feagan et al (COMMIT)(13) Adult CD 126 [1] IFX+MTX; [2] IFX+PCB 50 wks RCT 2008 Van Assche et al(14) Adult CD 80 [1] IFX+AZA; [2] IFX 104 wks Post-hoc analysis of 11 RCTs* 2013 Jones et al (27) Adult CD [1] Anti-TNF+IM [1a] IFX+IM [2] Anti-TNF [2a] IFX Post-hoc analysis of 4 IFX RCTs* 2009 Lichtenstein et al (25) Adult CD&UC 1383 [1] IFX+IM [2] IFX 30-54 wks Post-hoc analysis of 5 IFX RCTs* 2012 Lichtenstein et al (46) Adult CD&UC [1] IFX+IM [2] IFX [3] IM 30-54 wks